Please wait

Citations

  • 2006

  • Michal Vieth, Jeffrey J. Sutherland; Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs; J. Med. Chem., 2006, 49, 3451-34531

  • Peter J. Meek, ZhiWei Liu, LiFeng Tian, Ching Y. Wang, William J. Welsh, Randy J. Zauhar; Shape Signatures: speeding up computer aided drug discovery; Drug Discovery Today, Vol. 11, No. 19/20, 2006, 895-904.

  • 2007

  • Christopher Southan, Peter Varkonyi, Sorel Muresan; Complementarity Between Public and Commercial Databases: New Opportunities in Medicinal Chemistry Informatics; Current Topics in Medicinal Chemistry, 2007, 7, 1502-1508.

  • Paul D. Leeson, Brian Springthorpe; The influence of drug-like concepts on decision-making in medicinal chemistry; Nature Reviews: Drug Discovery, 2007, 6, 881-890.

  • D Rognan; Chemogenomic approaches to rational drug design; British Journal of Pharmacology, 2007, 152, 38-52.

  • 2008

  • Alex M. Aronov, Brian McClain, Cameron Stuver Moody, Mark A. Murcko; Kinase-likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology; J. Med. Chem., 2008, 51, 1214-1222.

  • Jonas Boström, Andrew Grant, edited by Raimund Mannhold; Molecular Drug Properties - Measurement and Prediction, Exploiting Ligand Conformations in Drug Design; Book from Wiley InterScience, Volume 37, 2008 Wiley-VCH Verlag GmbH & Co. KGaA.

  • Sung Jin Cho, Yaxiong Sun; Visual exploration of structure-activity relationship using maximum common framework; J Comput Aided Mol Des., 2008, 22, 571-578.

  • 2009

  • Josef Scheiber, Bin Chen, Mariusz Milik, Sai Chetan K. Sukuru, Andreas Bender, Dmitri Mikhailov, Steven Whitebread, Jacques Hamon, Kamal Azzaoui, Laszlo Urban, Meir Glick, John W. Davies, Jeremy L. Jenkins; Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis; J. Chem. Inf. Model., 2009, 49, 308-317.

  • Hongming Chen, Ulf Borjesson, Ola Engkvist, Thierry Kogej, Mats A. Svensson, Niklas Blomberg, Dirk Weigelt, Jeremy N. Burrows, Tim Lange; ProSAR: A New Methodology for Combinatorial Library Design; J. Chem. Inf. Model., 2009, 49 (3), 603-614.

  • Josefin Rosen, Johan Gottfries, Sorel Muresan, Anders Backlund, Tudor I. Oprea; Novel Chemical Space Exploration via Natural Products; J. Med. Chem., 2009, 52 (7), 1953-1962.

  • Christopher Southan, Peter Varkonyi, Sorel Muresan; Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds; Journal of Cheminformatics, 2009, 1:10, 1-17.

  • Frank Lovering, Jack Bikker, Christine Humblet; Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success; J. Med. Chem., 2009, 52, 6752-6756.

  • Christian Tyrchan, Niklas Blomberg, Ola Engkvist, Thierry Kogej, Sorel Muresan; Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds; Bioorg. Med. Chem. Lett. 2009, 19 (24), 6943-6947.

  • 2011

  • Christopher Southan, Kiran Boppana, Sarma A.R.P. Jagarlapudi, Sorel Muresan; Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds; Journal of Cheminformatics 2011, 3:14.

  • Dana E. Vanderwall, Nancy Yuen, Mohammad Al-Ansari, James Bailey, David Fram, Darren V.S. Green, Stephen Pickett, Giovanni Vitulli, Juan I. Luengo, June S. Almenoff; Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience; Drug Discovery Today, Vol. 16, No. 15/16, 2011, 646-653.

  • Paul D. Leeson, Stephen A. St-Gallay; The influence of the 'organizational factor' on compound quality in drug discovery; Nature Reviews: Drug Discovery, 2011, 10, 749-765.

  • 2013

  • Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, Sorel Muresan; Tracking 20 Years of Compound-to-Target Output from Literature and Patents; PLOS ONE, October 29, 2013.

  • 2014

  • Kiyoshi Hasegawa a, Kimito Funatsu; L-shaped PLS analysis ofmultiple inhibitory activities of adrenergic alpha receptors using ligand and protein matrices; Chemometrics and Intelligent Laboratory Systems 130 (2014) 166-171.

  • Aurelie Bornot, Carolyn Blackett, Ola Engkvist, Clare Murray, Claus Bendtsen; The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens; J Biomol Screen January 17, 2014 1087057113518966.

  • Have a Question?



    NOTE: To access this application, please use Google Chrome, IE, Firefox or Safari as your browser. Please make sure that JavaScript and style sheets are enabled in the browser. This site is best viewed at a resolution of 1024x768.
    Powered by